Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension

Completed

Conditions: Hypertension

First Posted Date: 2008-03-19

Last Posted Date: 2012-05-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 33247

Registration Number: NCT00638911

Special Survey Long-term Treatment With Tiotropium on COPD

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2008-03-18

Last Posted Date: 2014-06-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 385

Registration Number: NCT00638183

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Yurihonjo, Japan

BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment

Phase 2

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: BI 811283 (d 1 and 15)
Drug: BI 811283 (d1)
Drug: Cytarabine

First Posted Date: 2008-03-11

Last Posted Date: 2015-09-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 68

Registration Number: NCT00632749

Locations: 🇩🇪
1247.3.49004 Boehringer Ingelheim Investigational Site, Freiburg, Germany
🇩🇪
1247.3.49007 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪
1247.3.49005 Boehringer Ingelheim Investigational Site, Frankfurt/Main, Germany

and more 4 locations

Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium

First Posted Date: 2008-02-27

Last Posted Date: 2014-03-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2031

Registration Number: NCT00624377

Locations: 🇨🇳
Boehringer Ingelheim Investigational Site 1, Taipiei, Taiwan
🇨🇳
Boehringer Ingelheim Investigational Site 5, Taipiei, Taiwan
🇨🇳
Boehringer Ingelheim Investigational Site, Taoyuan, Taiwan

and more 4 locations

26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2008-02-26

Last Posted Date: 2014-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 838

Registration Number: NCT00624052

Locations: 🇪🇸
1235.8.34005 Boehringer Ingelheim Investigational Site, Santa Coloma de Gramanet, Spain
🇪🇸
1235.8.34004 Boehringer Ingelheim Investigational Site, Madrid, Spain
🇪🇸
1235.8.34001 Boehringer Ingelheim Investigational Site, Jerez de la Frontera (Cádiz), Spain

and more 89 locations

STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction

Phase 3

Completed

Conditions: Myocardial Infarction

Interventions: Drug: enoxaparin
Procedure: primary PCI
Procedure: catheterisation
Drug: tenecteplase
Drug: clopidogrel

First Posted Date: 2008-02-26

Last Posted Date: 2019-08-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1899

Registration Number: NCT00623623

Locations: 🇮🇹
1123.28.39001A Boehringer Ingelheim Investigational Site, Monza, Italy
🇫🇷
1123.28.3329A Boehringer Ingelheim Investigational Site, Aubervilliers Cedex, France
🇫🇷
1123.28.3329C Boehringer Ingelheim Investigational Site, Aubervilliers Cedex, France

and more 197 locations

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg
Drug: Placebo identical to BI 1356 5mg
Drug: BI 1356
Drug: Glimepiride

First Posted Date: 2008-02-25

Last Posted Date: 2014-01-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1560

Registration Number: NCT00622284

Locations: 🇺🇸
1218.20.10030 Boehringer Ingelheim Investigational Site, Topeka, Kansas, United States
🇺🇸
1218.20.10035 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
🇺🇸
1218.20.10003 Boehringer Ingelheim Investigational Site, Chula Vista, California, United States

and more 218 locations

Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: linagliptin

First Posted Date: 2008-02-22

Last Posted Date: 2014-02-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 503

Registration Number: NCT00621140

Locations: 🇮🇹
1218.16.39004 Boehringer Ingelheim Investigational Site, Catanzaro, Italy
🇮🇹
1218.16.39008 Boehringer Ingelheim Investigational Site, Genova, Italy
🇮🇹
1218.16.39001 Boehringer Ingelheim Investigational Site, Pisa, Italy

and more 66 locations

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

Phase 2

Completed

Conditions: Coronary Disease

Interventions: Drug: dabigatran etexilate
Drug: placebo

First Posted Date: 2008-02-22

Last Posted Date: 2014-03-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1878

Registration Number: NCT00621855

Locations: 🇨🇦
1160.67.11020 Boehringer Ingelheim Investigational Site, Sudbury, Ontario, Canada
🇨🇦
1160.67.11018 Boehringer Ingelheim Investigational Site, London, Ontario, Canada
🇧🇪
1160.67.32003 Boehringer Ingelheim Investigational Site, Hasselt, Belgium

and more 164 locations

Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2008-02-22

Last Posted Date: 2014-10-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 4918

Registration Number: NCT00621582

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy